Abstract:
A controlled release diltiazem dosage formulation comprising a plurality of active pellets coated with an extended release coating wherein the active pellets contain diltiazem or a pharmaceutically acceptable salt, a pharmaceutically acceptable inert seed and a binder and the extended release coating contains a water insoluble water permeable polymer, a channeling agent, a lubricant and optionally a surfactant. A single batch intermittent method of manufacturing a heterogeneous population of extended release pellets for use as a dosage formulation is also disclosed.
Abstract:
A controlled release antihyperglycemic tablet that does not contain an expanding polymer and comprising a core containing the antihyperglycemic drug, a semipermeable membrane coating the core and at least one passageway in the membrane.
Abstract:
The method for forming a flash memory cell mainly includes the steps as follows. At first, a semiconductor substrate having isolation regions thereon and having a well region provided between the isolation regions is provided. A tunnel oxide layer is formed on the well region and a first silicon layer is formed over the substrate. A dielectric layer is formed on the first silicon layer and a portion of the first silicon layer and the dielectric layer is removed to define a control gate opening within the first silicon layer on a portion of the well region. Next, the substrate is doped in the region under the control gate opening to adjust a threshold voltage of the flash memory cell. A gate oxide layer is grown from the substrate in the control gate opening and a second silicon layer is formed on the substrate to fill within the control gate opening and to cover the remaining dielectric layer. The second silicon layer, the dielectric layer, and the first silicon layer are then patterned to form a gate structure of the flash memory cell, and to leave a drain opening exposing a portion of the tunnel oxide on the well region. Finally, the substrate is doped to form a drain region in the substrate between the gate structure and one of the isolation regions.
Abstract:
The present invention relates to an improved structure of a piston for air-filing device by making use of air pressure formed as a result of the reciprocation action of piston within the cylinder to urge an air-tightness disc mounted at the top of the piston to close rapidly and to open instantaneously. At the simultaneous reciprocation action of the piston, the cylinder is provided with a rapid flowing in of air without passing through an air-inlet valve and the air is compressible. This facilitates the speed of compression of the entry air, and avoids the installation of the air-inlet valve.
Abstract:
A method of programming and erasing a triple-poly split-gate flash memory. The memory cell is programmed by substrate hot-electron injection and erased by the tunneling effect and an inversion layer near the drain region. Such programming/erasing procedures can achieve uniform injection with low programming current and high injection efficiency.
Abstract:
A split-gate source side injection flash EEPROM array structure and method of fabrication that utilizes the same polysilicon layer to form the control gate and the floating gate. Furthermore, there is a tunneling oxide layer underneath the floating gate, a gate oxide layer underneath the control gate, and that the tunneling oxide layer has a thickness smaller than the gate oxide layer. Since the control gate and the floating gate are formed on a silicon layer through the same patterning process, polysilicon spacers can be used to control the gap width between the control gate and the floating gate. Therefore, a reliable and reproducible flash cell array can be produced.
Abstract:
A controlled release dosage form which comprises:(a) a homogeneous compressed core which comprises a compressed granulation of:(i) particles of a calcium channel blocker compound coated with an enteric polymer that are dispersed onto a solid pharmaceutical filler; and(b) a continuous compressed outer layer around said homogeneous compressed core which comprises a compressed granulation of:(i) one or more pharmaceutically acceptable polymers which form a hydrogel in which calcium channel blocker compound is dispersed.
Abstract:
A method for making planar silicon-based inductor structure with improved Q is disclosed. This method includes the steps of: (a) providing a lightly-doped P-type substrate as a starting wafer; (b) forming a preliminary oxide layer on the lightly-doped P-type substrate; (c) forming a first oxide layer from the preliminary oxide layer enclosing a predetermined epitaxial area; (d) depositing an epitaxial layer in the epitaxial area using intrinsic doping; (e) forming a second oxide layer which covers both the epitaxial layer and the first oxide layer, and is merged with the first oxide layer to thus form a contiguous inter-connected inductor oxide layer; (f) forming a metal line according to a planar inductor pattern so as to form a silicon-based inductor structure. The epitaxial layer has a resistivity of at least 2 K ohm-cm. The planar silicon-based inductor improves the Q value by reducing or stopping current losses into the substrate.
Abstract:
The present invention provides a controlled release dosage form which may be made using a blend having an internal drug containing phase and an external phase which comprises a polyethylene glycol polymer which has a weight average molecular weight of from 3000 to 10000. The dosage formulation may be pressed into tablets or it may be formed directly into discrete orally administrable shapes by pressing the blend into a cavity which is sized to accept a volume of the blend which is equivalent to one dosage unit. A plurality of cavities may be formed in a strip of plastic which may be sealed after the blend of the invention is pressed in place to form a plurality of unit doses of a drug.
Abstract:
The invention is directed to a method for the modification of the rate of release of a drug from a hydrogel which is based on the use of an effective amount of a pharmaceutically acceptable ionizable compound that is capable of providing a substantially zero-order release rate of drug from the hydrogel.